Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9353132
APP PUB NO 20150080339A1
SERIAL NO

14382356

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure relates to boron-based 4-hydroxytamoxifen and endoxifen prodrugs and the synthesis of the same. Further, the present disclosure teaches the utilization of the boron-based 4-hydroxytamoxifen and endoxifen prodrugs in a treatment for breast cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
XAVIER UNIVERSITY OF LOUISIANA1 DREXEL DRIVE NEW ORLEANS LA 70125

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Jiang, Quan New Orleans, US 30 128
Wang, Guangdi New Orleans, US 15 13
Zhang, Qiang New Orleans, US 790 5324
Zheng, Shilong New Orleans, US 9 16
Zhong, Qiu New Orleans, US 16 45

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 30, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00